Quantum BioPharma (STU:0K91) E10: €-91.42 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0K91 Quantum BioPharma Ltd STU:0K91
38 GF Score
Price €2.64
! 5 Warning Signs
View Full Analysis

What is Quantum BioPharma E10?

Quantum BioPharma STU:0K91 -6.84% 38 E10 is €-91.42 as of Mar. 2026. GuruFocus rates STU:0K91 with a GF Score™ of 38/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Quantum BioPharma's adjusted earnings per share data for the three months ended in Mar. 2026 was €-2.647. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-91.42 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-21), Quantum BioPharma's current stock price is €2.642. Quantum BioPharma's E10 for the quarter that ended in Mar. 2026 was €-91.42. Quantum BioPharma's Shiller PE Ratio of today is .


Quantum BioPharma  (STU:0K91) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Quantum BioPharma E10 Related Terms


Quantum BioPharma E10 Historical Data

* Premium members only.

The historical data trend for Quantum BioPharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quantum BioPharma E10 Chart

Quantum BioPharma Annual Data
Trend Aug16 Aug17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -103.49

Quantum BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -103.49 -91.42

STU:0K91 vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Quantum BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quantum BioPharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quantum BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Quantum BioPharma's Shiller PE Ratio falls into.


STU:0K91
38GF Score
Quantum BioPharma Ltd STU:0K91
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quantum BioPharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Quantum BioPharma's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-2.647/132.2623*132.2623
=-2.647

Current CPI (Mar. 2026) = 132.2623.

Quantum BioPharma Quarterly Data

per share eps CPI Adj_EPS
201605 -0.066 101.765 -0.086
201608 -0.119 101.686 -0.155
201611 -0.007 101.607 -0.009
201702 -0.088 102.476 -0.114
201705 -0.029 103.108 -0.037
201708 -0.051 103.108 -0.065
201711 -0.043 103.740 -0.055
201802 0.401 104.688 0.507
201806 -34.014 105.557 -42.619
201809 21.666 105.636 27.127
201812 -147.279 105.399 -184.816
201903 -102.539 106.979 -126.773
201906 -98.154 107.690 -120.550
201909 -99.868 107.611 -122.745
201912 -109.023 107.769 -133.801
202003 -67.649 107.927 -82.902
202006 -28.283 108.401 -34.509
202009 -59.048 108.164 -72.203
202012 -12.208 108.559 -14.873
202103 -20.202 110.298 -24.225
202106 -19.422 111.720 -22.993
202109 -8.288 112.905 -9.709
202112 -7.478 113.774 -8.693
202203 -8.853 117.646 -9.953
202206 -7.379 120.806 -8.079
202209 -12.474 120.648 -13.675
202212 -9.780 120.964 -10.693
202303 -15.785 122.702 -17.015
202306 -8.399 124.203 -8.944
202309 -1.647 125.230 -1.739
202312 -2.638 125.072 -2.790
202403 -3.156 126.258 -3.306
202406 -4.831 127.522 -5.011
202409 -3.937 127.285 -4.091
202412 -2.226 127.364 -2.312
202503 -3.265 129.181 -3.343
202506 -2.800 129.892 -2.851
202509 -1.065 130.287 -1.081
202512 -0.606 130.366 -0.615
202603 -2.647 132.262 -2.647

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-91.42 mean?
Quantum BioPharma (STU:0K91) has a E10 of €-91.42 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Quantum BioPharma and its competitors.
Is Quantum BioPharma's E10 too high?
Quantum BioPharma's current E10 is €-91.42. Overall, Quantum BioPharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Quantum BioPharma's E10 compare to VRTX and REGN?
Quantum BioPharma's E10 of €-91.42 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Quantum BioPharma and its competitors. Quantum BioPharma's current E10 is €-91.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quantum BioPharma stock overvalued right now?
Quantum BioPharma (STU:0K91) has a current E10 of €-91.42. The current E10 is €-91.42. Quantum BioPharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Quantum BioPharma (STU:0K91), the current E10 is €-91.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quantum BioPharma Business Description

Other Exchanges QNTM:USAQNTM:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
38GF Score

Get the complete analysis for STU:0K91

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.64
Price